title: [Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease].
abstract: BACKGROUND
  There is limited information on the optimal use of thiopurinic immunomodulators in inflammatory bowel disease (IBD) and the dosage, efficacy and toxicity of these drugs has not been clearly established.
  
  
  OBJECTIVE
  To evaluate clinical outcomes and the toxicity of thiopurinic immunomodulators in clinical practice (effectiveness), as well as possible associated variables.
  
  
  METHODS
  Data were obtained from a database of patients with ulcerative colitis and Crohn's disease who started treatment with azathioprine or 6-mercaptopurine with an identical predetermined schedule and follow-up. Remission, relapse and toxicity were defined and analyzed and their relationship with clinical, biologic and demographic variables was evaluated with multivariate analysis.
  
  
  RESULTS
  We evaluated 150 courses of treatment in 126 patients. Treatment was given to induce clinical remission in 118 courses and 62% of the patients reached this outcome, which was maintained for a mean of 52 months. The only variable associated with poor response was perianal disease. Adverse events were detected in 34% of the courses and were the main cause of treatment withdrawal. Factors significantly associated with withdrawal due to adverse events were starting with full doses of thiopurinic drugs (OR, 4.26; 95% CI, 1.12-16.32) and cotreatment with infliximab (OR, 5.6; 95% CI, 1.17-27.1).
  
  
  CONCLUSIONS
  Some clinical variables such as disease phenotype, the use of full doses of thiopurinic drugs from the start of treatment, and co-treatments can have a notable influence on adverse effects and thus on the effectiveness of this therapy in IBD.
authors.affiliation: Servicio de Medicina Digestiva. Hospital Universitario La Fe. Valencia. España. gbastidap@sepd.org
authors.forename: Guillermo
authors.initials: G
authors.lastname: Bastida Paz
authors.forename: Pilar
authors.initials: P
authors.lastname: Nos Mateu
authors.forename: Mariam
authors.initials: M
authors.lastname: Aguas Peris
authors.forename: Belén
authors.initials: B
authors.lastname: Beltrán Niclós
authors.forename: María
authors.initials: M
authors.lastname: Rodríguez Soler
authors.forename: Julio
authors.initials: J
authors.lastname: Ponce García
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D004066:Digestive System Diseases / Q000209:etiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010342:Patient Acceptance of Health Care; D012074:Remission Induction; D012086:Reoperation; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine